News Headlines Article

Health Insurer Mergers Will Pressure Pharma Over High-Cost Drugs
The Wall Street Journal

As the nation’s biggest health insurers jockey for supremacy, drug makers should brace for added pressure because doctors are likely to face stingier reimbursement over the next few years. And cancer treatments, in particular, are expected to be targeted, according to a report from Moody’s Investor Service.

The changes reflect ongoing efforts insurers are making to diversify and cut costs in response to the Affordable Care Act, which is now prompting a flurry of merger talks.

Commands